ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).
- ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).
- Increasing the available supply of BCG is intended to address shortages for the combination therapy with ANKTIVA.
- “The collaboration between Serum Institute of India and ImmunityBio will undoubtedly transform the way we approach cancer treatment.
- We look forward to exploring ANKTIVA in combination with BCG in non-muscle invasive bladder cancer (NMIBC) and across other tumor types.